Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer
NCT06178445Phase 2Active, not recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and trastuzumab in cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Objective Response Rate at 6 months. Started Apr 2024; status: active, not recruiting.
02
Drugs
03
Conditions
cholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NCT06178445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06178445.